This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.
Drugs
August 2016
Antithrombin alfa (ATryn) for pre-eclampsia in pre-term women
Pre-eclampsia is a condition that affects some pregnant women during the second half of their pregnancy. Signs include high blood pressure and protein in the urine. Most cases are mild, but the condition can lead to serious complications for both mother and baby. Antithrombin alfa is a new drug for the treatment of pre-eclampsia that …
Drugs
March 2016
Nausea and vomiting in pregnancy, also known as morning sickness, is very common in early pregnancy. It is unpleasant, but usually stops by weeks 16 to 20 of pregnancy. Some women get a very severe form of nausea and vomiting called hyperemesis gravidarum, which can be very serious and needs specialist treatment in hospital. There …
Diagnostics
October 2012
UPDATED: Amniotic Fluid Lactate™ monitoring system for dysfunctional labour
The Amniotic Fluid Lactate™ (AFL) monitoring system is designed to aid clinical decisions during dysfunctional labour. It consists of a monitor and a probe which measures the level of lactate in the amniotic fluid. This correlates with lactate levels in the uterus. High uterine lactate levels may indicate that treatment with oxytocin would be less …
Diagnostics
September 2012
UPDATED: Placental Growth Factor based tests for the diagnosis of pre-eclampsia
The Alere PlGF test and the Roche sFlt-1/PlGF ratio test may provide a new way of diagnosing pre-eclampsia in pregnant women who have signs and symptoms of the condition. The Alere PlGF test measures a biomarker called placental growth factor (PlGF) and the Roche sFlt-1/PlGF ratio test measures PlGF and soluble FMS-like tyrosine kinase-1 (sFlt-1) …
Diagnostics
August 2012
UPDATED: DuoFertility ovulation prediction system to aid natural conception
DuoFertility is a non-invasive system that monitors a woman’s basal body temperature to determine the time of ovulation. It is designed for home use by couples having difficulty in conceiving where no cause has been identified. Unlike other temperature-based systems where readings are taken once a day, this device continuously measures a woman’s temperature, using …
Diagnostics
January 2012
DELFIA® Xpress PlGF kit antenatal screening test to predict risk of pre-eclampsia
The DELFIA® Xpress PlGF kit may provide a new way of screening pregnant women to predict their chances of getting pre-eclampsia. This biochemical test measures the level of a biomarker called placental growth factor (PlGF) in the woman’s blood. It can be performed in antenatal clinics alongside other screening tests. It is claimed that, along …
Diagnostics
September 2011
Amniotic Fluid Lactate™ monitoring system for dysfunctional labour
The Amniotic Fluid Lactate™ (AFL) monitoring system is designed to aid clinical decisions during dysfunctional labour. It consists of a monitor and a probe which measures the level of lactate in the amniotic fluid. This correlates with lactate levels in the uterus. High uterine lactate levels may indicate that treatment with oxytocin would be less …
Diagnostics
August 2011
Placental Growth Factor based tests for the diagnosis of pre-eclampsia
The Alere PlGF test and the Roche sFlt-1/PlGF ratio tests may provide a new way of diagnosing pre-eclampsia in pregnant women who have signs and symptoms of the condition. The Alere PlGF test measures a biomarker called placental growth factor (PlGF) and the Roche sFlt-1/PlGF ratio test measures PlGF and soluble FMS-like tyrosine kinase-1 (sFlt-1) …
Diagnostics
July 2011
DuoFertility ovulation prediction system to aid natural conception
DuoFertility is a non-invasive system that monitors a woman’s basal body temperature to determine the time of ovulation. It is designed for home use by couples having difficulty in conceiving where no cause has been identified. Unlike other temperature-based systems where readings are taken once a day, this device continuously measures a woman’s temperature, using …
Reviews
March 2009
REVIEW – New and emerging diagnostic tests for screening of infections during pregnancy
Around 700,000 women become pregnant in the United Kingdom (UK) every year. Under the UK National Screening Programme, all women are offered screening tests between 8-12 weeks’ of gestation for syphilis, hepatitis B virus (HBV), and human immunodeficiency virus (HIV) infections, and rubella susceptibility. The current system of antenatal screening for infections is inefficient for …